Go Ad-Free
    My Alerts
    Budget Express 2026

    co-presented by

    • JIO BlackRock

    ASSOCIATE SPONSORS

    • Sunteck
    • SBI
    • Emirates
    HomeNewsAjanta pharmaceuticals

    Ajanta Pharmaceuticals

    Jump to

    • Buy Ajanta Pharmaceuticals; target of Rs 1385: ICICI Direct

      ICICI Direct is bullish on Ajanta Pharmaceuticals recommended buy rating on the stock with a target price of Rs 1385 in its research report dated February 02, 2023.

    • Buy Ajanta Pharmaceuticals; target of Rs 1505: ICICI Direct

      ICICI Direct is bullish on Ajanta Pharmaceuticals recommended buy rating on the stock with a target price of Rs 1505 in its research report dated November 04, 2022.

    • Buy Ajanta Pharmaceuticals; target of Rs 1495: ICICI Direct

      ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1495 in its research report dated July 29, 2022.

    • Hold Ajanta Pharmaceuticals; target of Rs 1305: ICICI Direct

      ICICI Direct recommended hold rating on Ajanta Pharmaceuticals with a target price of Rs 1305 in its research report dated June 22, 2022.

    • Buy Ajanta Pharmaceuticals; target of Rs 1955: ICICI Direct

      ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1955 in its research report dated May 11, 2022.

    • Buy Ajanta Pharmaceuticals; target of Rs 2605: ICICI Direct

      ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 2605 in its research report dated February 02, 2021.

    • Buy Ajanta Pharmaceuticals; target of Rs 2250: ICICI Direct

      ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 2250 in its research report dated May 01, 2021.

    • Buy Ajanta Pharmaceuticals; target of Rs 1960: ICICI Direct

      ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1960 in its research report dated November 04, 2020.

    • Buy Ajanta Pharmaceuticals; target of Rs 1810: ICICI Direct

      ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1810 in its research report dated July 31, 2020.

    • Buy Ajanta Pharmaceuticals; target of Rs 1730: ICICI Direct

      ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1730 in its research report dated May 22, 2020.

    • Hold Ajanta Pharmaceuticals; target of Rs 1010: ICICI Direct

      ICICI Direct recommended hold rating on Ajanta Pharmaceuticals with a target price of Rs 1010 in its research report dated August August 01, 2019.

    • Ajanta Pharma bets on India, US markets to beat African tenders slowdown

      The company, a major player in anti-malarial drugs in Africa, saw its business decline by 49 percent in FY19 compared to the previous year due to softening of tender business.

    • Hold Ajanta Pharmaceuticals; target of Rs 1060: ICICI Direct

      ICICI Direct recommended hold rating on Ajanta Pharmaceuticals with a target price of Rs 1060 in its research report dated May 02, 2019.

    • Hold Ajanta Pharmaceuticals; target of Rs 1100: ICICI Direct

      ICICI Direct recommended hold rating on Ajanta Pharmaceuticals with a target price of Rs 1100 in its research report dated February 01, 2019.

    • Hold Ajanta Pharmaceuticals; target of Rs 1190: ICICI Direct

      ICICI Direct recommended hold rating on Ajanta Pharmaceuticals with a target price of Rs 1190 in its research report dated May 03, 2018.

    • Dabur in talks to buy Ajanta's 30-plus brand - report

      Dabur India is in talks to buy the 30-Plus multi-vitamin supplement brand from Ajanta Pharmaceuticals for less than 500 million rupees, the Economic Times reported on Monday.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347